IXICO PLC · LSE:IXI

IXICO — H1 2023 Earnings Presentation

30 slides from IXICO's earnings presentation, May 23, 2023

  1. Slide 1: Advanced analytics. Intelligent insights. H1-23 Interim Results

    Slide 1: Advanced analytics. Intelligent insights. H1-23 Interim Results

    Advanced analytics. Intelligent insights. H1-23 Interim Results 23rd May 2023 Giulio Cerroni Grant Nash Robin Wolz CEO CFO CSO

  2. Slide 2: Nonregulated Disclaimer

    Slide 2: Nonregulated Disclaimer

    Nonregulated Disclaimer This presentation is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which incl

  3. Slide 3: Driven By Our Purpose

    Slide 3: Driven By Our Purpose

    Driven By Our Purpose Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience. We will focus on developing and deploying breakthrough data analytics, at scale, through our remote-access technology pla

  4. Slide 4: Financial Highlights H1-2023

    Slide 4: Financial Highlights H1-2023

    Financial Highlights H1-2023 4

  5. Slide 5: Revenue profile, reflecting impact of large PIII HD trial

    Slide 5: Revenue profile, reflecting impact of large PIII HD trial

    Revenue profile, reflecting impact of large PIII HD trial Revenues delivered and forecast1 2020 to 2024 (£m) 9.5 9.2 8.6 ̶ 15% expected CAGR in revenues over 7.8 4 years excluding loss of PIII trial 7.0 - 2.2 ̶ 2023 sees final comparative revenue 4.0 0.1 impact of large PIII trial cessation. 5.1 ̶ I

  6. Slide 6: Transition in the business, late phase single client reliance to early phase client diversity

    Slide 6: Transition in the business, late phase single client reliance to early phase client diversity

    Transition in the business, late phase single client reliance to early phase client diversity Revenues (£m) Gross Margin (%) EBITDA (£m) 0.9 4.9 67 68 0.7 4.6 60 0.5 3.9 3.2 46 -0.6 H1-20 H1-21 H1-22 H1-23 H1-20 H1-21 H1-22 H1-23 H1-20 H1-21 H1-22 H1-23 ̶ Revenues in H1-23 reflect final impact of ̶

  7. Slide 7: Strong balance sheet; positive operating cash inflow

    Slide 7: Strong balance sheet; positive operating cash inflow

    Strong balance sheet; positive operating cash inflow Cash (£m) Net Assets (£m) Closing Order Book (£m) 7.9 12.5 11.9 11.2 6.7 21.7 5.8 9.1 18.8 5.0 16.0 13.3 2020 2021 2022 H1-23 2020 2021 2022 H1-23 2020 2021 2022 H1-23 ̶ £5.0m cash position ̶ £11.9m net asset position ̶ H1-23 order book impacted b

  8. Slide 8: Strong contract wins, but several small trial descopes

    Slide 8: Strong contract wins, but several small trial descopes

    Strong contract wins, but several small trial descopes 12-month order book bridge (£m) 7.9 11.6 3.0 12.6 13.3 H1-22 order book 12 month contract wins 12 month revenues 12 month trial descopes & fx H1-23 order book ̶ £0.6m announced 8-Dec-22 ̶ £2.3m small trial descopes/ cessations ̶ £0.1m negative f

  9. Slide 9: Underlying progress in order book diversification

    Slide 9: Underlying progress in order book diversification

    Underlying progress in order book diversification Order book by phase: FY20 -vs- H1-23 % Order book by client: Top 5 -vs- other FY20 H1-23 H1-23 FY22 FY21 FY20 3 2 1 NH Other 3 2 1 NH Other 0% 20% 40% 60% 80% 100% Client #1 Client #2 Client #3 Client #4 Client #5 Other 9 PUBLIC © IXICO plc 2023

  10. Slide 10: TrialTracker: infrastructure to support 'precision in neuroscience' strategy

    Slide 10: TrialTracker: infrastructure to support 'precision in neuroscience' strategy

    TrialTracker: infrastructure to support ‘precision in neuroscience’ strategy Standardised capture, analysis and reporting Site of regulatory compliant clinical data Sponsor Pharma / Biotech MR images Clinical sponsor interpretation standardized Clinical development expert reads Support the developme

  11. Slide 11: Precision in Neuroscience

    Slide 11: Precision in Neuroscience

    Precision in Neuroscience 11

  12. Slide 12: Precision in Neuroscience Strategy

    Slide 12: Precision in Neuroscience Strategy

    Precision in Neuroscience Strategy Build Innovate Penetrate Bridge Enhance …commercial … by extending …early phase trials …the clinical trial …growth via reach & iCRO our data assets to grow into later to clinical practice partnerships and scale & leading AI clinical phases divide M&A biomarker port

  13. Slide 13: Precision in Neuroscience

    Slide 13: Precision in Neuroscience

    Precision in Neuroscience Recruitment to trials is slow, with some trials recruiting at a rate as low as 0.2 patients per “ We estimate that a successful biomarker for AD would slash patient screen fail rates by 50%, site per month and requiring 1-2 years to saving drug sponsors $30-100m recruit pat

  14. Slide 14: US FDA Commissioner is already thinking about Post-Market questions

    Slide 14: US FDA Commissioner is already thinking about Post-Market questions

    US FDA Commissioner is already thinking about Post-Market questions “ There’s a question of who should be treated. Is it everybody? Is it a particular subgroup based on amyloid or some other characteristic? We’re now at a phase of technology where I feel like we shouldn’t be using “ marketing to mak

  15. Slide 15: ARIA detection for post-market surveillance

    Slide 15: ARIA detection for post-market surveillance

    ARIA detection for post-market surveillance 15

  16. Slide 16: Status update – key anti-amyloid monoclonal antibodies

    Slide 16: Status update – key anti-amyloid monoclonal antibodies

    Status update – key anti-amyloid monoclonal antibodies Lecanemab (Leqembi) Donanemab Aducanumab (Aduhelm) Gantenerumab • Positive Ph III results • Positive Ph III results • Accelerated approval on • Negative Ph III results presented in Nov. 2022 presented in May 2023 positive Ph II / inconclusive pr

  17. Slide 17: ARIA are the key side effect of approved anti-amyloid drugs

    Slide 17: ARIA are the key side effect of approved anti-amyloid drugs

    Amyloid Related Imaging Abnormalities (ARIA) are the key side effect of approved Anti - Amyloid drugs • ARIA safety assessment from MRI is a core requirement of anti-amyloid AD clinical trials and well understood in research centres, but less so in general and private settings • Aduhelm® and Leqembi

  18. Slide 18: IXICO is well-placed to support and develop an ARIA solution

    Slide 18: IXICO is well-placed to support and develop an ARIA solution

    IXICO is well-placed to support and develop an ARIA solution 2-5yrs Widespread • Stage I: IXICO’s track record and Stage III access to Pharma. Requirement is reimbursement and prescription an extension of ARIA safety monitoring already provided by IXICO in clinical trials • Stage II: IXICO’s Assessa

  19. Slide 19: Bridge Pillar: Post-market safety assessment

    Slide 19: Bridge Pillar: Post-market safety assessment

    Bridge Pillar: Post-market safety assessment – Central Imaging read platform to monitor critical safety findings – Biogen PML Pilot: Developed with clinical Multiple Sclerosis experts – Validated and used in multiple territories across Europe 19 PUBLIC © IXICO plc 2023

  20. Slide 20: Summary highlights

    Slide 20: Summary highlights

    Summary highlights 20

  21. Slide 21: Summary highlights

    Slide 21: Summary highlights

    Summary highlights • Final period of comparative revenue impact of large PIII trial cessation. • Increased diversity of revenue base, de-risking trial descopes • £11.6m of contract wins in the last 12 months • Order book now tilted to earlier stage trials which means significant latent value from fu

  22. Slide 22: Appendix

    Slide 22: Appendix

    Appendix 22

  23. Slide 23: Significant, growing unmet clinical need in neurological diseases

    Slide 23: Significant, growing unmet clinical need in neurological diseases

    Significant, growing unmet clinical need in neurological diseases Increasing costs Dementia is the only major Total worldwide Ageing population & burden to global cause of death we can’t cost of dementia [2] The number of 131.5m healthcare prevent, slow people in the world down or cure [1] with deme

  24. Slide 24: Recent press releases in AD Anti-Amyloid treatments

    Slide 24: Recent press releases in AD Anti-Amyloid treatments

    Recent press releases in AD Anti-Amyloid treatments Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease https://www.globenewswire.com/news-release/2023/03/22/2631934/0/en/Roche-announces-collaboration-with-Lilly-to- enhance-early-diagnosis-of-Alzheimer-s-diseas

  25. Slide 25: Major shareholders (>3% holding) as at May-23

    Slide 25: Major shareholders (>3% holding) as at May-23

    Major shareholders (>3% holding) as at May-23 Percentage Shareholder Date acquired No. of Shares allocation BGF Investment Management May-19 8,924,000 18% Octopus Investments May-18 6,408,400 13% Gresham House May-18 5,357,100 11% Amati Global Investors May-18 5,031,300 10% CIP Merchant Capital Limi

  26. Slide 26: H1-23 Summary Income Statement

    Slide 26: H1-23 Summary Income Statement

    H1-23 Summary Income Statement: H1-23 H1-22 FY2022 Income Statement (Unaudited) (Unaudited) (Audited) Revenues ̶ Reduced revenues as final tail of large PIII HD trial impact £’000 £’000 £’000 seen in revenues; ̶ Rebalancing of order book resulting in increased early Revenues £3,203 £3,922 £8,643 pha

  27. Slide 27: H1-23 Summary Balance Sheet

    Slide 27: H1-23 Summary Balance Sheet

    H1-23 Summary Balance Sheet: H1-23 H1-22 FY2022 Balance Sheet (Unaudited) (Unaudited) (Audited) Tangible & Intangible assets ̶ Continued investment to support future growth £’000 £’000 £’000 ̶ Next generation image data platform nearing completion Tangible & intangible assets 6,016 4,537 5,404 ̶ Rel

  28. Slide 28: H1-23 Summary Cashflow

    Slide 28: H1-23 Summary Cashflow

    H1-23 Summary Cashflow: H1-23 H1-22 FY2022 Cashflow (Unaudited) (Unaudited) (Audited) Closing cash ̶ £5.0m cash held to support organic growth £’000 £’000 £’000 Operating cash flows Cashflow from operating 173 218 1,424 ̶ £0.2m inflow H1-23 reflecting similar cash generation to H1-22. Cashflow from

  29. Slide 29: Thank you

    Slide 29: Thank you

    Thank you BUSINESS USE ONLY © IXICO plc 2019

  30. Slide 30: BUSINESS USE ONLY © IXICO plc 2019

    Slide 30: BUSINESS USE ONLY © IXICO plc 2019

    BUSINESS USE ONLY © IXICO plc 2019

Source: Internet Archive copy of ixico.com

More decks from IXICO PLC

All 11 IXICO decks